Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic effects of ketohexokinase inhibition in non-alcoholic fatty liver disease
2021-006677-26Phase 2Completed
- Sponsor
- Maastricht University
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatotic liver disease (MASLD) comparing PF-06835919 with Placebo (2 arms). Primary endpoint: Hepatic insulin sensitivity. Started Apr 2022; status: completed.
02
Drugs
PF-06835919
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2021-006677-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006677-26.